Does High PCT Warrant Longer Therapy?

Overview

A secondary analysis of the BALANCE trial indicates that elevated procalcitonin (PCT) levels after 7 days of antibiotic therapy may not be a reliable indicator for extending antibiotic therapy. The study found no significant benefit in extending antibiotic therapy based on high PCT levels.

Background

Understanding the role of procalcitonin (PCT) in guiding antibiotic therapy duration is crucial, especially in the context of bloodstream infections. Elevated PCT levels have been associated with increased mortality, yet their utility in determining the length of antibiotic treatment remains unclear.

Data Highlights

Key Findings

• High PCT levels (≥ 250 pg/mL) were associated with increased 90-day mortality (22% vs. 6% for lower levels).
• No significant differences in ICU mortality or hospital-free days were observed between high and low PCT groups.
• Extending antibiotic therapy to 14 days did not improve outcomes in patients with elevated PCT levels.
• Host factors may contribute to PCT elevations, limiting its use as a standalone guide for antibiotic duration.
• The analysis included only 125 patients, limiting the statistical power of the findings.

Clinical Implications

Clinicians should be cautious in using elevated PCT levels as a sole indicator for extending antibiotic therapy duration.

Conclusion

The analysis indicates that elevated PCT levels may not warrant prolonged antibiotic therapy.

Related Resources & Content

1. Wright JK, Muscedere J, JAMA Network Open, 2026 -- Procalcitonin to Guide 7 vs 14 Days of Antibiotics in Bloodstream Infections: A Secondary Analysis of the BALANCE Trial
2. Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock 2026 | SCCM
3. Antibiotic Treatment for 7 versus 14 Days in Patients with Bloodstream Infections | New England Journal of Medicine
4. the asco post — Testosterone Recovery After Androgen-Deprivation Therapy Linked to Improved Survival in High-Risk Prostate Cancer
5. The ASCO Post — Optimal Duration of Checkpoint Inhibition in Melanoma Is No More Than 2 Years
6. The ASCO Post — Optimal Timing of Hormonal Therapy for Biochemically Recurrent Prostate Cancer Remains Unclear
7. The ASCO Post — Should We Treat Rising PSA in Men With Castrate Androgen Levels?
8. Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock 2026 | SCCM
9. Antibiotic Treatment for 7 versus 14 Days in Patients with Bloodstream Infections | New England Journal of Medicine
10. Procalcitonin to Guide 7 vs 14 Days of Antibiotics in Bloodstream Infections: A Secondary Analysis of the BALANCE Trial | Infectious Diseases | JAMA Network Open | JAMA Network